Nikolai Naoumov

Nikolai V. Naoumov (born 1952) is a British Bulgarian physician-scientist, and Professor of Hepatology at University College London, whose career has spun clinical/academic research and drug development for liver diseases.[1]

Career

Naoumov’s career in liver diseases started in 1979 in Bulgaria, where he set up the first specialised laboratory for molecular diagnosis of hepatitis viruses; described the first cases of hepatitis Delta virus-induced liver disease;[2] published the first textbook on abdominal ultrasound in "The echographic diagnosis in internal medicine",[3] and was appointed as Associate Professor in liver diseases at the Medical Academy, Sofia. Between 1981-1990, during his postgraduate training, Naoumov received three research fellowships from The Wellcome Trust (UK) held at the Institute of Liver Studies, King's College London, to focus on liver immunology; molecular biology and liver pathology. Naoumov then joined the Institute of Liver Studies, King’s College London (1991), leading a research group with projects dedicated to hepatitis B and hepatitis C studies. He was appointed as senior lecturer (1996) at University College London (UCL) and honorary consultant physician at UCL Hospitals. Naoumov led the viral hepatitis clinical service, as well as a research group at the Institute of Hepatology and in 2005 was appointed Professor of Hepatology at UCL.[4] Naoumov later took the role of Global Head, Therapeutic Hepatology and Transplantation at Novartis, where he retired in 2021.[1]

Professional affiliations and roles

Naoumov is a Fellow of the Royal College of Physicians and the Royal College of Pathologists (UK). He is also Senior Fellow of the Association of Physicians of Great Britain and Ireland[5] and was elected as Fellow of the American Association for the Study of Liver Disease (AASLD). Since 2016, Naoumov serves as Trustee and Board Member of the Swiss Liver Research Foundation, Bern.[6] He has also served as Trustee and later Scientific Advisor to the Foundation for Liver Research, London (2007-2020); President of the International Medical Club; and Member of the Scientific Committee of the European Association for the Study of Liver (EASL) (1991-1994).[7] Naoumov serves on many advisory boards, for InSphero,[8] Ciclofilin Pharmaceuticals [9] and Hepion Pharmaceuticals.[10] Naoumov has served as editor for liver diseases of the European Journal of Clinical Investigation, associate editor of the Journal of Hepatology, and special section editor of Journal of Hepatology.[11]

Research

Naoumov's research integrates immunology, molecular biology and translational medicine in more than 300 peer reviewed publications.[12] Naoumov's primary clinical and research interests are in hepatitis B – immunology and novel therapies,[13][14][15] hepatitis C,[16] liver transplantation for viral liver diseases,[17] development of investigational drugs,[18][19] and digital pathology, particularly for quantitative assessment of liver fibrosis [20]

References

  1. 1 2 "University College London".
  2. ↑ Naoumov, N. V.; Gueorgiev, A.; Ognyanov, M.; Maleev, A. (1986). "Infection with hepatitis delta virus in patients with fulminant hepatitis B and chronic HBsAg carriers in Bulgaria". Hepato-Gastroenterology. 33 (2): 49–51. PMID 3721387.
  3. ↑ The echographic diagnosis in internal medicine”. I Tomov and N Naoumov, Sofia 1992, ISBN 954-420-011-8
  4. ↑ "People 2005-2006". 2 July 2018.
  5. ↑ "Fellows Directory - AoPGBI". 29 August 2022.
  6. ↑ "Swissliver foundation".
  7. ↑ "ILC 2021 Basic Science Seminar".
  8. ↑ "InSphero Further Strengthens Scientific Advisory Board for Liver Diseases by Appointing Professor Nikolai Naoumov - InSphero". 9 February 2022.
  9. ↑ "Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board" (Press release). 4 February 2016.
  10. ↑ "Nikolai Naoumov, M.D., Ph.D. – Hepion Pharmaceuticals".
  11. ↑ "How does ribavirin improve interferon-a response rates in hepatitis C virus infection?". www.journal-of-hepatology.eu.
  12. ↑ "Google Scholar".
  13. ↑ Rossol, S.; Marinos, G.; Carucci, P.; Singer, M. V.; Williams, R.; Naoumov, N. V. (1997). "Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B". The Journal of Clinical Investigation. 99 (12): 3025–3033. doi:10.1172/JCI119498. PMC 508155. PMID 9185527.
  14. ↑ Neumann, Avidan U.; Phillips, Sandra; Levine, Idit; Ijaz, Samreen; Dahari, Harel; Eren, Rachel; Dagan, Shlomo; Naoumov, Nikolai V. (2010). "Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells†". Hepatology. 52 (3): 875–885. doi:10.1002/hep.23778. PMC 3086357. PMID 20593455.
  15. ↑ Phillips, Sandra; Chokshi, Shilpa; Riva, Antonio; Evans, Alexander; Williams, Roger; Naoumov, Nikolai V. (2010). "CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions". The Journal of Immunology. 184 (1): 287–295. doi:10.4049/jimmunol.0902761. PMID 19949099.
  16. ↑ Naoumov, N. V.; Petrova, E. P.; Thomas, M. G.; Williams, R. (1998). "Presence of a newly described human DNA virus (TTV) in patients with liver disease". Lancet. 352 (9123): 195–197. doi:10.1016/S0140-6736(98)04069-0. PMID 9683209.
  17. ↑ Naoumov, Nikolai V.; Lopes, A.Ross; Burra, Patrizia; Caccamo, Lucio; Iemmolo, Rosa M.; De Man, Robert A.; Bassendine, Margaret; O'Grady, John G.; Portmann, Bernard C.; Anschuetz, Gaya; Barrett, Catherine A.; Williams, Roger; Atkins, Mark (2001). "Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation". Journal of Hepatology. 34 (6): 888–894. doi:10.1016/S0168-8278(01)00039-3. PMID 11451173.
  18. ↑ Liaw, Y. F.; Gane, E.; Leung, N.; Zeuzem, S.; Wang, Y.; Lai, C. L.; Heathcote, E. J.; Manns, M.; Bzowej, N.; Niu, J.; Han, S. H.; Hwang, S. G.; Cakaloglu, Y.; Tong, M. J.; Papatheodoridis, G.; Chen, Y.; Brown, N. A.; Albanis, E.; Galil, K.; Naoumov, N. V.; GLOBE Study Group (2009). "2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B". Gastroenterology. 136 (2): 486–495. doi:10.1053/j.gastro.2008.10.026. PMID 19027013.
  19. ↑ Naoumov, N. V. (2014). "Cyclophilin inhibition as potential therapy for liver diseases". Journal of Hepatology. 61 (5): 1166–1174. doi:10.1016/j.jhep.2014.07.008. PMID 25048953.
  20. ↑ Naoumov, N. V.; Brees, D.; Loeffler, J.; Chng, E.; Ren, Y.; Lopez, P.; Tai, D.; Lamle, S.; Sanyal, A. J. (2022). "Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH". Journal of Hepatology. 77 (5): 1399–1409. doi:10.1016/j.jhep.2022.06.018. PMID 35779659.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.